Allogeneic stem cell transplantation

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The survival of patients with multiple myeloma (MM) has improved over the past decade [1]. The most significant gains have been in patients without high-risk molecular markers. Despite these gains, multiple myeloma remains fatal and curative strategies are needed. Allogeneic stem cell transplant (Allo-SCT) includes both myeloablative and nonmyeloablative or “reduced intensity conditioning” (RIC) transplants. Allogeneic transplant is appealing in theory because it avoids infusion of stem cells contaminated with myeloma cells and because there can be a beneficial graft vs. myeloma effect [2]. The role of Allo-SCT in myeloma, however, is debated due to the high mortality and morbidity. The high treatment-related mortality and significant toxicity from graft-versus-host disease (GVHD) have limited the role of this procedure in the treatment of myeloma.

Original languageEnglish (US)
Title of host publicationMultiple Myeloma
Subtitle of host publicationDiagnosis and Treatment
PublisherSpringer New York
Pages125-130
Number of pages6
ISBN (Electronic)9781461485209
ISBN (Print)9781461485193
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Allogeneic stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this

    Lacy, M. (2014). Allogeneic stem cell transplantation. In Multiple Myeloma: Diagnosis and Treatment (pp. 125-130). Springer New York. https://doi.org/10.1007/978-1-4614-8520-9_11